158 related articles for article (PubMed ID: 21473913)
21. Calcineurin inhibitors recruit protein kinases JAK2 and JNK, TLR signaling and the UPR to activate NF-κB-mediated inflammatory responses in kidney tubular cells.
González-Guerrero C; Ocaña-Salceda C; Berzal S; Carrasco S; Fernández-Fernández B; Cannata-Ortiz P; Egido J; Ortiz A; Ramos AM
Toxicol Appl Pharmacol; 2013 Nov; 272(3):825-41. PubMed ID: 23958496
[TBL] [Abstract][Full Text] [Related]
22. Calcineurin inhibitors and hypertension: a role for pharmacogenetics?
Moes AD; Hesselink DA; Zietse R; van Schaik RH; van Gelder T; Hoorn EJ
Pharmacogenomics; 2014 Jun; 15(9):1243-51. PubMed ID: 25141899
[TBL] [Abstract][Full Text] [Related]
23. The impact of calcineurin inhibitors on graft survival.
Rush D
Transplant Rev (Orlando); 2013 Jul; 27(3):93-5. PubMed ID: 23743217
[TBL] [Abstract][Full Text] [Related]
24. Genomic-based biomarkers of drug-induced nephrotoxicity.
Davis JW; Kramer JA
Expert Opin Drug Metab Toxicol; 2006 Feb; 2(1):95-101. PubMed ID: 16863471
[TBL] [Abstract][Full Text] [Related]
25. Identification of genomic biomarkers for concurrent diagnosis of drug-induced renal tubular injury using a large-scale toxicogenomics database.
Kondo C; Minowa Y; Uehara T; Okuno Y; Nakatsu N; Ono A; Maruyama T; Kato I; Yamate J; Yamada H; Ohno Y; Urushidani T
Toxicology; 2009 Nov; 265(1-2):15-26. PubMed ID: 19761811
[TBL] [Abstract][Full Text] [Related]
26. [Review of clinical trials on minimization and interruption of calcineurin inhibitors (CNIs) and protocols without CNIs in the transplantation of different organs (kidney, heart, and liver)].
Albano L
Nephrol Ther; 2009 Dec; 5 Suppl 6():S371-8. PubMed ID: 20129448
[TBL] [Abstract][Full Text] [Related]
27. Hot-topic debate on kidney function: renal-sparing approaches are beneficial.
Durand F
Liver Transpl; 2011 Nov; 17 Suppl 3():S43-9. PubMed ID: 21796759
[TBL] [Abstract][Full Text] [Related]
28. Calcineurin inhibitors: a double-edged sword.
Ume AC; Wenegieme TY; Williams CR
Am J Physiol Renal Physiol; 2021 Mar; 320(3):F336-F341. PubMed ID: 33225712
[TBL] [Abstract][Full Text] [Related]
29. Chronic kidney disease after nonrenal solid organ transplantation: a histological assessment and utility of chronic allograft damage index scoring.
Kubal C; Cockwell P; Gunson B; Jesky M; Hanvesakul R; Dronavalli V; Bonser RS; Neil D
Transplantation; 2012 Feb; 93(4):406-11. PubMed ID: 22217532
[TBL] [Abstract][Full Text] [Related]
30. Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients.
Mulgaonkar S; Kaufman DB
Clin Transplant; 2014 Nov; 28(11):1209-24. PubMed ID: 25142257
[TBL] [Abstract][Full Text] [Related]
31. Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.
Nashan B
Transpl Int; 2004 Jul; 17(6):279-85. PubMed ID: 15221123
[TBL] [Abstract][Full Text] [Related]
32. New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone.
Bobadilla NA; Gamba G
Am J Physiol Renal Physiol; 2007 Jul; 293(1):F2-9. PubMed ID: 17429034
[TBL] [Abstract][Full Text] [Related]
33. Identification and measurement of genomic biomarkers of nephrotoxicity.
Goodsaid FM
J Pharmacol Toxicol Methods; 2004; 49(3):183-6. PubMed ID: 15172014
[TBL] [Abstract][Full Text] [Related]
34. Calcineurin inhibitor-free immunosuppression in kidney transplantation.
Guerra G; Srinivas TR; Meier-Kriesche HU
Transpl Int; 2007 Oct; 20(10):813-27. PubMed ID: 17645419
[TBL] [Abstract][Full Text] [Related]
35. Chronic renal allograft injury: early detection, accurate diagnosis and management.
Pascual J; Pérez-Sáez MJ; Mir M; Crespo M
Transplant Rev (Orlando); 2012 Oct; 26(4):280-90. PubMed ID: 22902496
[TBL] [Abstract][Full Text] [Related]
36. [Minimization or avoidance of calcineurin inhibitors after renal transplantation].
Xue C; Ji ZG
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Jun; 31(3):280-3. PubMed ID: 19621509
[TBL] [Abstract][Full Text] [Related]
37. YB-1 increases glomerular, but decreases interstitial fibrosis in CNI-induced nephropathy.
Gibbert L; Hermert D; Wang J; M Breitkopf D; Alidousty C; Neusser M; Cohen CD; Gröne E; Macheleidt I; Rauen T; Braun GS; Floege J; Ostendorf T; Raffetseder U
Clin Immunol; 2018 Sep; 194():67-74. PubMed ID: 30018024
[TBL] [Abstract][Full Text] [Related]
38. Reviewing the evidence for de novo immunosuppression with sirolimus.
Flechner SM
Transplant Proc; 2008 Dec; 40(10 Suppl):S25-8. PubMed ID: 19100902
[TBL] [Abstract][Full Text] [Related]
39. Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity.
Campistol JM; Grinyó JM
Transplantation; 2001 Jun; 71(11 Suppl):SS42-51. PubMed ID: 11583488
[TBL] [Abstract][Full Text] [Related]
40. The pathophysiology of endothelin in complications after solid organ transplantation: a potential novel therapeutic role for endothelin receptor antagonists.
Raina A; Horn ET; Benza RL
Transplantation; 2012 Nov; 94(9):885-93. PubMed ID: 23037008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
